Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis

Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis

AIM. To evaluate the efficacy and safety of Denosumab (Prolia), a first-line osteoporosis (OP) medication that is a fully human monoclonal antibody to the receptor activator of nuclear factor κВ ligand (RANKL), within an open-label observational study. MATERIALS AND METHODS. Patients aged 50 years o...

Full description

Bibliographic Details
Main Authors: O B Ershova, O M Lesniak, K Iu Belova, A V Nazarova, A V Manovitskaia, T M Musaeva, R M Mustaev, R Z Nurlygaianov, L Ia Rozhinskaia, I A Skripnikova, N V Toroptsova
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2014-10-01
Series:Терапевтический архив
Subjects:
osteoporosis
c-terminal telopeptide
prolia
denosumab
Online Access:https://ter-arkhiv.ru/0040-3660/article/view/31587

Internet

https://ter-arkhiv.ru/0040-3660/article/view/31587

Similar Items